image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 13.16
-2.52 %
$ 765 M
Market Cap
13.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one EMBC stock under the worst case scenario is HIDDEN Compared to the current market price of 13.2 USD, Embecta Corp. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one EMBC stock under the base case scenario is HIDDEN Compared to the current market price of 13.2 USD, Embecta Corp. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one EMBC stock under the best case scenario is HIDDEN Compared to the current market price of 13.2 USD, Embecta Corp. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
1.12 B REVENUE
0.21%
167 M OPERATING INCOME
-24.70%
78.3 M NET INCOME
11.22%
35.7 M OPERATING CASH FLOW
-47.27%
-15.8 M INVESTING CASH FLOW
40.38%
-73.4 M FINANCING CASH FLOW
-50.72%
262 M REVENUE
-8.46%
28.7 M OPERATING INCOME
9.54%
-26.3 M NET INCOME
-180.14%
-5.3 M OPERATING CASH FLOW
-19.92%
-1.5 M INVESTING CASH FLOW
0.00%
-45.2 M FINANCING CASH FLOW
-23.50%
Balance Sheet Embecta Corp.
image
Current Assets 761 M
Cash & Short-Term Investments 268 M
Receivables 248 M
Other Current Assets 246 M
Non-Current Assets 524 M
Long-Term Investments 0
PP&E 290 M
Other Non-Current Assets 234 M
Current Liabilities 374 M
Accounts Payable 91 M
Short-Term Debt 12.9 M
Other Current Liabilities 270 M
Non-Current Liabilities 1.65 B
Long-Term Debt 1.6 B
Other Non-Current Liabilities 54.1 M
EFFICIENCY
Earnings Waterfall Embecta Corp.
image
Revenue 1.12 B
Cost Of Revenue 388 M
Gross Profit 735 M
Operating Expenses 568 M
Operating Income 167 M
Other Expenses 88.5 M
Net Income 78.3 M
RATIOS
65.46% GROSS MARGIN
65.46%
14.85% OPERATING MARGIN
14.85%
6.97% NET MARGIN
6.97%
-10.61% ROE
-10.61%
6.09% ROA
6.09%
31.97% ROIC
31.97%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Embecta Corp.
image
Net Income 78.3 M
Depreciation & Amortization 36.2 M
Capital Expenditures -15.8 M
Stock-Based Compensation 26.3 M
Change in Working Capital -47.7 M
Others 96.7 M
Free Cash Flow 19.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Embecta Corp.
image
Wall Street analysts predict an average 1-year price target for EMBC of $19.3 , with forecasts ranging from a low of $12 to a high of $26 .
EMBC Lowest Price Target Wall Street Target
12 USD -8.81%
EMBC Average Price Target Wall Street Target
19.3 USD 46.91%
EMBC Highest Price Target Wall Street Target
26 USD 97.57%
4. DIVIDEND ANALYSIS
0.74% DIVIDEND YIELD
0.15 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Embecta Corp.
image
Sold
0-3 MONTHS
50.8 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Feb 13, 2025
Sell 50.8 K USD
Morris Milton Mayo
Director
- 3100
16.3816 USD
1 year ago
Feb 12, 2024
Bought 32.5 K USD
Melcher David F
Director
+ 2000
16.25 USD
1 year ago
Sep 08, 2023
Bought 98.3 K USD
Melcher David F
Director
+ 6233
15.7662 USD
1 year ago
Aug 10, 2023
Bought 109 K USD
Kurdikar Devdatt
President and CEO
+ 5000
21.81 USD
1 year ago
Aug 10, 2023
Bought 102 K USD
Mann Jeffrey Z
SVP, GC, Head Corp. Dev., Secy
+ 4700
21.67 USD
1 year ago
Aug 10, 2023
Bought 100 K USD
Elguicze Jacob
SVP and CFO
+ 4625
21.6637 USD
2 years ago
Feb 15, 2023
Bought 102 K USD
Melcher David F
Director
+ 3100
32.925 USD
2 years ago
Feb 15, 2023
Bought 101 K USD
Melcher David F
Director
+ 3100
32.51 USD
7. News
embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that Jake Elguicze, embecta's Chief Financial Officer, will present at the J.P. Morgan Global Leveraged Finance Conference in Miami on Tuesday, February 25, 2025 at 3:00 p.m. ET. globenewswire.com - 1 week ago
Embecta Corp. (EMBC) Q1 2025 Earnings Call Transcript Embecta Corp. (NASDAQ:EMBC ) Q1 2025 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - President & Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Ryan Schiller - Wolfe Research Operator Good day, and thank you for standing by. Welcome, ladies and gentlemen, to the Embecta Fiscal First Quarter 2025 Earnings Conference Call. seekingalpha.com - 3 weeks ago
Embecta Corp. (EMBC) Tops Q1 Earnings and Revenue Estimates Embecta Corp. (EMBC) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.61 per share a year ago. zacks.com - 3 weeks ago
Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2024. globenewswire.com - 3 weeks ago
embecta Announces Quarterly Cash Dividend PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 14, 2025 to stockholders of record at the close of business on February 28, 2025. globenewswire.com - 3 weeks ago
embecta to Report Fiscal First Quarter 2025 Financial Results PARSIPPANY, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 6, 2025. globenewswire.com - 1 month ago
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog. zacks.com - 1 month ago
4 MedTech Stocks Poised to Thrive Under Second Trump Presidency Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR. zacks.com - 1 month ago
3 Stocks Trading Near 52-Week High With Room to Rise Further Investors target stocks that have been on a bullish run lately. Stocks like EMBC, NFG and REVG are seeing price strength and the momentum is likely to continue. zacks.com - 1 month ago
3 Medical Services Stocks to Buy to Counter Labor Shortage Woes The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most. zacks.com - 1 month ago
4 Best-Bargain PEG Stocks That Value Investors Love Here are four stocks that fit our screening criteria. These are GAP, EMBC, BLBD and ZIM. zacks.com - 2 months ago
embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference PARSIPPANY, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. globenewswire.com - 2 months ago
8. Profile Summary

Embecta Corp. EMBC

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 765 M
Dividend Yield 0.74%
Description Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Contact 300 Kimball Drive, Parsippany, NJ, 07054 https://www.embecta.com
IPO Date March 22, 2022
Employees 2100
Officers Mr. Pravesh Khandelwal Vice President & Head of Investor Relations Mr. Jeffrey Z. Mann Senior Vice President, General Counsel, Head of Business Development & Corporate Secretary Mr. Anthony M. Roth Vice President, Chief Accounting Officer & Corporate Controller Mr. Shaun Curtis Senior Vice President of Global Manufacturing & Supply Chain Ms. Colleen Riley Senior Vice President & Chief Technology Officer Mr. Tom Blount Senior Vice President & President of North America Mr. Jacob P. Elguicze Senior Vice President & Chief Financial Officer Ms. Ginny Blocki Senior Vice President of Global Marketing & Product Management Mr. Devdatt Kurdikar Ph.D. President, Chief Executive Officer & Director Ms. Jean M. Casner Senior Vice President & Chief Human Resources Officer